Literature DB >> 32343678

Circular RNA-ZNF532 regulates diabetes-induced retinal pericyte degeneration and vascular dysfunction.

Qin Jiang1,2, Chang Liu2, Chao-Peng Li3, Shan-Shan Xu2, Mu-Di Yao2, Hui-Min Ge1,2, Ya-Nan Sun4, Xiu-Miao Li1, Shu-Jie Zhang4, Kun Shan4, Bai-Hui Liu4, Jin Yao1,2, Chen Zhao4,5,6, Biao Yan4,5,6.   

Abstract

Diabetic retinopathy (DR) is the leading cause of blindness in working-age adults. Vascular pericyte degeneration is the predominant clinical manifestation of DR, yet the mechanism governing pericyte degeneration is poorly understood. Circular RNAs (circRNAs) play important roles in multiple biological processes and disease progression. Here, we investigated the role of circRNA in pericyte biology and diabetes-induced retinal vascular dysfunction. cZNF532 expression was upregulated in pericytes under diabetic stress, in the retinal vessels of a diabetic murine model, and in the vitreous humor of diabetic patients. cZNF532 silencing reduced the viability, proliferation, and differentiation of pericytes and suppressed the recruitment of pericytes toward endothelial cells in vitro. cZNF532 regulated pericyte biology by acting as a miR-29a-3p sponge and inducing increased expression of NG2, LOXL2, and CDK2. Knockdown of cZNF532 or overexpression of miR-29a-3p aggravated streptozotocin-induced retinal pericyte degeneration and vascular dysfunction. By contrast, overexpression of cZNF532 or inhibition of miR-29a-3p ameliorated human diabetic vitreous-induced retinal pericyte degeneration and vascular dysfunction. Collectively, these data identify a circRNA-mediated mechanism that coordinates pericyte biology and vascular homeostasis in DR. Induction of cZNF532 or antagonism of miR-29a-3p is an exploitable therapeutic approach for the treatment of DR.

Entities:  

Keywords:  Diabetes; Noncoding RNAs; Ophthalmology; Retinopathy

Mesh:

Substances:

Year:  2020        PMID: 32343678      PMCID: PMC7324174          DOI: 10.1172/JCI123353

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina.

Authors:  Q Wang; F Pfister; A Dorn-Beineke; F vom Hagen; J Lin; Y Feng; H P Hammes
Journal:  Diabetologia       Date:  2010-03-26       Impact factor: 10.122

Review 2.  Endothelial/pericyte interactions.

Authors:  Annika Armulik; Alexandra Abramsson; Christer Betsholtz
Journal:  Circ Res       Date:  2005-09-16       Impact factor: 17.367

3.  Eye vessels saved by rescuing their pericyte partners.

Authors:  David Antonetti
Journal:  Nat Med       Date:  2009-11       Impact factor: 53.440

4.  Differentiating vitreous proteomes in proliferative diabetic retinopathy using high-performance liquid chromatography coupled to tandem mass spectrometry.

Authors:  Hao Wang; Le Feng; Jianwen Hu; Chunlei Xie; Fang Wang
Journal:  Exp Eye Res       Date:  2012-12-28       Impact factor: 3.467

Review 5.  The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy.

Authors:  Alistair J Barber; Thomas W Gardner; Steven F Abcouwer
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-28       Impact factor: 4.799

Review 6.  The emerging role of circular RNAs in transcriptome regulation.

Authors:  S Huang; B Yang; B J Chen; N Bliim; U Ueberham; T Arendt; M Janitz
Journal:  Genomics       Date:  2017-06-26       Impact factor: 5.736

7.  Pericytes and the pathogenesis of diabetic retinopathy.

Authors:  Hans-Peter Hammes; Jihong Lin; Oliver Renner; Moshe Shani; Andrea Lundqvist; Christer Betsholtz; Michael Brownlee; Urban Deutsch
Journal:  Diabetes       Date:  2002-10       Impact factor: 9.461

Review 8.  Circular RNAs: diversity of form and function.

Authors:  Erika Lasda; Roy Parker
Journal:  RNA       Date:  2014-12       Impact factor: 4.942

Review 9.  Theranostic impact of NG2/CSPG4 proteoglycan in cancer.

Authors:  Pier Andrea Nicolosi; Alice Dallatomasina; Roberto Perris
Journal:  Theranostics       Date:  2015-02-15       Impact factor: 11.556

10.  Inhibition of Sema4D/PlexinB1 signaling alleviates vascular dysfunction in diabetic retinopathy.

Authors:  Jie-Hong Wu; Ya-Nan Li; An-Qi Chen; Can-Dong Hong; Chun-Lin Zhang; Hai-Ling Wang; Yi-Fan Zhou; Peng-Cheng Li; Yong Wang; Ling Mao; Yuan-Peng Xia; Quan-Wei He; Hui-Juan Jin; Zhen-Yu Yue; Bo Hu
Journal:  EMBO Mol Med       Date:  2020-01-13       Impact factor: 12.137

View more
  34 in total

1.  Targeting circular RNA-MET for anti-angiogenesis treatment via inhibiting endothelial tip cell specialization.

Authors:  Mu-Di Yao; Qin Jiang; Yan Ma; Yan Zhu; Qiu-Yang Zhang; Ze-Hui Shi; Chen Zhao; Biao Yan
Journal:  Mol Ther       Date:  2022-01-07       Impact factor: 11.454

Review 2.  Interplay between circular RNA, microRNA, and human diseases.

Authors:  Bimaljeet Kour; Suruchi Gupta; Ravail Singh; Yengkhom Sophiarani; Prosenjit Paul
Journal:  Mol Genet Genomics       Date:  2022-01-27       Impact factor: 3.291

3.  Lipotoxicity-induced circGlis3 impairs beta cell function and is transmitted by exosomes to promote islet endothelial cell dysfunction.

Authors:  Li Xiong; Li Chen; Liting Wu; Weiman He; Dubo Chen; Zishan Peng; Jin Li; Xiaonan Zhu; Lei Su; Yanbing Li; Yingying Gong; Haipeng Xiao
Journal:  Diabetologia       Date:  2021-11-09       Impact factor: 10.122

4.  Comprehensive circular RNA expression profiling with associated ceRNA network in orbital venous malformation.

Authors:  Jie Yu; Peiwei Chai; Yixiong Zhou; Renbing Jia; Yefei Wang
Journal:  Mol Vis       Date:  2022-05-20       Impact factor: 2.711

Review 5.  Circular RNAs: Novel target of diabetic retinopathy.

Authors:  Huan-Ran Zhou; Hong-Yu Kuang
Journal:  Rev Endocr Metab Disord       Date:  2021-03-24       Impact factor: 6.514

Review 6.  Circular RNAs in kidney disease and cancer.

Authors:  Anton Jan van Zonneveld; Malte Kölling; Roel Bijkerk; Johan M Lorenzen
Journal:  Nat Rev Nephrol       Date:  2021-08-11       Impact factor: 28.314

Review 7.  Targeting circular RNAs as a therapeutic approach: current strategies and challenges.

Authors:  Alina T He; Jinglei Liu; Feiya Li; Burton B Yang
Journal:  Signal Transduct Target Ther       Date:  2021-05-21

Review 8.  The Vitreous Ecosystem in Diabetic Retinopathy: Insight into the Patho-Mechanisms of Disease.

Authors:  Siva S R Iyer; Mollie K Lagrew; Stephanie M Tillit; Ramak Roohipourmoallai; Samuel Korntner
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

9.  circFTO upregulates transforming growth factor-alpha through sponging miR-148a-3p to regulate high glucose-induced ARPE-19 cells injury.

Authors:  Yan Huang; Xueyao Li; Lu Jiang; Chunyan Mo; Miao Luo; Ken Hu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

10.  Circ_001209 aggravates diabetic retinal vascular dysfunction through regulating miR-15b-5p/COL12A1.

Authors:  Fang Wang; Meixia Zhang
Journal:  J Transl Med       Date:  2021-07-07       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.